A multiple ascending subcutaneous (SC) dose study of MEDI-563, a humanized anti-IL-5Rα monoclonal antibody, in adult asthmatics Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
PK/PD, safety and tolerability of a human anti-IL-1B monoclonal antibody (ACZ885) in healthy subjects Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006
Efficacy of an anti-IL13 monoclonal antibody, lebrikizumab, in adults with inadequately controlled asthma is enhanced in those with high periostin levels Source: Annual Congress 2011 - New treatments for airway disease Year: 2011
Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021
Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Population pharmacokinetics of tralokinumab, an investigational anti-IL-13 monoclonal antibody, in asthmatic and healthy adults Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012
Tolerability assessment of a recombinant humanized monoclonal anti-IgE antibody (omalizumab) as a treatment for seasonal allergic rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 116s Year: 2002
Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
A phase I single escalating intravenous (IV) dose of MEDI 563, an anti-IL5Rα antibody, in atopic asthma Source: Annual Congress 2008 - New treatments for asthma Year: 2008
Phase 2, mutlicenter, double-blind study of CNTO 148, a human monoclonal anti-TNF α antibody, in symptomatic patients with severe persistent asthma Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007
Preclinical development of an IL-13 neutralising antibody, CAT-354, for the treatment of human asthma Source: Eur Respir J 2005; 26: Suppl. 49, 367s Year: 2005
Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
A double-blind, placebo-controlled, study to assess the pharmacokinetics, safety and tolerability of multiple ascending intravenous doses of CAT 354, a recombinant human anti-IL13 antibody, in subjects with moderate asthma Source: Annual Congress 2008 - New treatments for asthma Year: 2008
A novel anti-IgE immunotherapeutic, RP01, induces anti-IgE antibodies in human subjects; data from a phase I study Source: Eur Respir J 2007; 30: Suppl. 51, 622s Year: 2007
Late Breaking Abstract - Preclinical study of anti-interleukin-4 alpha single domain antibody with therapeutic potential in asthma by oral inhalation Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Efficacy of inhaled anti-IL-13 mAb in a mouse model of asthma Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011
The effects of efalizumab, an anti-CD11a monoclonal antibody (hu1124), on allergen-induced airway inflammation in atopic asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 350s Year: 2001
Novel inhaled delivery of anti-IL-13 mAb (Fab fragment): preclinical efficacy in allergic asthma Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
MEMP1972A, an anti-M1 prime monoclonal antibody, reduces serum IgE in healthy and allergic rhinitis subjects Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma Source: Eur Respir J 2013; 41: 330-338 Year: 2013